Sanyou Biopharmaceuticals & Yugong Biotech Forge Strategic Enzyme Development Alliance
CompanyDeals

Sanyou Biopharmaceuticals & Yugong Biotech Forge Strategic Enzyme Development Alliance

Grand Pharmaceutical & Glenmark Specialty Secure China NMPA Approval for Ryaltris Nasal Spray
CompanyDrug

Grand Pharmaceutical & Glenmark Specialty Secure China NMPA Approval for Ryaltris Nasal Spray

Lepu Biopharma Secures FDA IND Clearance for CDH17‑Targeted ADC MRG007
CompanyDrug

Lepu Biopharma Secures FDA IND Clearance for CDH17‑Targeted ADC MRG007

Novartis Wins FDA Approval for Remibrutinib Tablets – First BTK Inhibitor for Chronic Spontaneous Urticaria
CompanyDrug

Novartis Wins FDA Approval for Remibrutinib Tablets – First BTK Inhibitor for Chronic Spontaneous Urticaria

Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment
CompanyDeals

Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment

DualityBio Secures FDA Fast‑Track Designation for EGFR/HER3 Bispecific ADC AVZO‑1418
CompanyDrug

DualityBio Secures FDA Fast‑Track Designation for EGFR/HER3 Bispecific ADC AVZO‑1418

Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform
Others

Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform

Roche Announces Positive Phase III Results for Fenebrutinib in Relapsing & Primary‑Progressive Multiple Sclerosis
CompanyDrug

Roche Announces Positive Phase III Results for Fenebrutinib in Relapsing & Primary‑Progressive Multiple Sclerosis

Simcere Launches Phase II Trial of T‑Reg‑Selective IL‑2 Fusion (SIM0278) for Moderate‑to‑Severe Atopic Dermatitis in China
CompanyDrug

Simcere Launches Phase II Trial of T‑Reg‑Selective IL‑2 Fusion (SIM0278) for Moderate‑to‑Severe Atopic Dermatitis in China

Gaush Meditech’s Subsidiary Secures China Registration for Integrated Ophthalmic Electrophysiology System
CompanyMedical Device

Gaush Meditech’s Subsidiary Secures China Registration for Integrated Ophthalmic Electrophysiology System

Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005
CompanyDeals

Brise Pharma Closes RMB 200 M Series A to Fund Pivotal Phase III Trial of First‑in‑Class CGRP Small‑Molecule Analgesic BR005

Mabwell’s 9MW3811 Gains NMPA Approval to Launch World‑First IL‑11‑Targeting Phase 2 Trial for Pathological Scarring
CompanyDrug

Mabwell’s 9MW3811 Gains NMPA Approval to Launch World‑First IL‑11‑Targeting Phase 2 Trial for Pathological Scarring